| Epidemiology of anxiety disorders in the 21st century B Bandelow, S Michaelis Dialogues in clinical neuroscience 17 (3), 327, 2015 | 931 | 2015 |
| World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders … B Bandelow, J Zohar, E Hollander, S Kasper, HJ Möller, ... The World Journal of Biological Psychiatry 9 (4), 248-312, 2008 | 818 | 2008 |
| Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology DS Baldwin, IM Anderson, DJ Nutt, B Bandelow, A Bond, JRT Davidson, ... Journal of Psychopharmacology 19 (6), 567-596, 2005 | 701 | 2005 |
| Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder A Broocks, B Bandelow, G Pekrun, A George, T Meyer, U Bartmann, ... American Journal of Psychiatry 155 (5), 603-609, 1998 | 520 | 1998 |
| Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the … DS Baldwin, IM Anderson, DJ Nutt, C Allgulander, B Bandelow, ... Journal of Psychopharmacology 28 (5), 403-439, 2014 | 507 | 2014 |
| Assessing the efficacy of treatments for panic disorder and agoraphobia: II. The Panic and Agoraphobia Scale. B Bandelow International clinical psychopharmacology, 1995 | 381 | 1995 |
| Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with borderline personality disorder and healthy controls B Bandelow, J Krause, D Wedekind, A Broocks, G Hajak, E Rüther Psychiatry research 134 (2), 169-179, 2005 | 373 | 2005 |
| Efficacy of treatments for anxiety disorders: a meta-analysis B Bandelow, M Reitt, C Röver, S Michaelis, Y Görlich, D Wedekind International Clinical Psychopharmacology 30 (4), 183-192, 2015 | 367 | 2015 |
| Guidelines for the pharmacological treatment of anxiety disorders, obsessive–compulsive disorder and posttraumatic stress disorder in primary care B Bandelow, L Sher, R Bunevicius, E Hollander, S Kasper, J Zohar, ... International journal of psychiatry in clinical practice 16 (2), 77-84, 2012 | 341 | 2012 |
| Treatment of anxiety disorders B Bandelow, S Michaelis, D Wedekind Dialogues in clinical neuroscience 19 (2), 93, 2017 | 257 | 2017 |
| WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders. World Federation of Societies of Biological Psychiatry (WFSBP … B Bandelow, J Zohar, E Hollander, S Kasper, HJ Möller World J Biol Psychiatry 9 (4), 248-312, 2008 | 235 | 2008 |
| What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? B Bandelow, DS Baldwin, OT Dolberg, HF Andersen, DJ Stein The Journal of clinical psychiatry 67 (9), 1428-1434, 2006 | 216 | 2006 |
| Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders B Bandelow, U Seidler-Brandler, A Becker, D Wedekind, E Rüther The World Journal of Biological Psychiatry 8 (3), 175-187, 2007 | 205 | 2007 |
| Early traumatic life events, parental rearing styles, family history of mental disorders, and birth risk factors in patients with social anxiety disorder B Bandelow, AC Torrente, D Wedekind, A Broocks, G Hajak, E Rüther European archives of psychiatry and clinical neuroscience 254 (6), 397-405, 2004 | 199 | 2004 |
| Neuropeptide S receptor gene—converging evidence for a role in panic disorder K Domschke, A Reif, H Weber, J Richter, C Hohoff, P Ohrmann, ... Molecular psychiatry 16 (9), 938-948, 2011 | 185 | 2011 |
| Panic and Agoraphobia Scale (PAS). B Bandelow Hogrefe & Huber Publishers, 1999 | 182 | 1999 |
| Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with panic disorder B Bandelow, C Späth, GÁ Tichauer, A Broocks, G Hajak, E Rüther Comprehensive psychiatry 43 (4), 269-278, 2002 | 170 | 2002 |
| Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition B Bandelow, D Baldwin, M Abelli, B Bolea-Alamanac, M Bourin, ... The World Journal of Biological Psychiatry 18 (3), 162-214, 2017 | 166 | 2017 |
| Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo-and … B Bandelow, G Chouinard, J Bobes, A Ahokas, I Eggens, S Liu, ... International Journal of Neuropsychopharmacology 13 (3), 305-320, 2010 | 163 | 2010 |
| WCA recommendations for the long-term treatment of generalized anxiety disorder C Allgulander, B Bandelow, E Hollander, SA Montgomery, DJ Nutt, ... CNS Spectr 8 (Suppl 1), 53-61, 2003 | 163 | 2003 |
Oliver GruberSection for Experimental Psychopathology and Neuroimaging, Department of General PsychiatryBestätigte E-Mail-Adresse bei med.uni-heidelberg.de
